For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.